Explore the latest advancements in denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases in ...

A retrospective observational study found no significant differences in progression-free survival or safety in patients with colorectal cancers in Japan treated with ABP 215, Amgen’s bevacizumab ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market ...

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...

April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She ...

Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and ...